FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop
Executive Summary
Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints
You may also be interested in...
Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte
Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4
Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte
Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16